艾迪注射液联合化疗在非小细胞肺癌中可行性研究.docVIP

艾迪注射液联合化疗在非小细胞肺癌中可行性研究 　　[摘要] 目的 研究艾迪注射液联合化疗用于非小细胞肺癌治疗中的效果。方法 在该院2015年1月―2016年10月来该院就诊的非小细胞肺癌患者中方便选取135例，随机分成对照组和观察组，对照组患者给予化疗治疗，观察组患者在对照组的化疗基础上给予艾迪注射液治疗，对比两组患者的治疗效果指标值。结果 观察组患者的治疗有效率79.10%高于对照组的58.82%（P0.05）；观察组患者在血红蛋白减少、白细胞减少、皮疹、胃肠道反应以及肝功能损害不良反应的发生率上均比对照组患者更低（P0.05）；观察组患者治疗后生活质量各项指标的评分均显著高于对照组（P0.05） 结论 艾迪注射液与化疗联合用于非小细胞肺癌治疗是安全可行的，有助于提高抗肿瘤效果，减少不良反应的发生，提高患者的生活质量，值得在临床上推广应用。 　　[关键词] 艾迪注射液；非小细???肺癌；化疗；细胞因子；不良反应 　　[中图分类号] R97 [文献标识码] A [文章编号] 1674-0742（2017）05（c）-0126-03 　　[Abstract] Objective To research the effect of aidi injection and chemotherapy in the non-small cell lung cancer. Methods 135 cases of patients with non-small cell lung cancer diagnosed in our hospital from January 2015 to October 2016 were conveniently selected and randomly divided into two groups， the control group adopted the chemotherapy， while the observation group adopted the aidi injection on the basis of the control group， and the treatment effect was compared between the two groups. Results The treatment effective rate in the observation group was higher than that in the control group， （79.10% vs 58.82%）（P0.05）， and the incidence rate of reduced hemoglobin， reduced white blood cells， skin rashes， gastrointestinal reactions and impaired liver function in the observation group were lower than those in the control group（P0.05），The scores of the quality of life index in the observation group were significantly higher than those in the control group（P0.05）. Conclusion The aidi injection and chemotherapy in the non-small cell lung cancer is safe and feasible， which contributes to improving the anti-tumor effect， reducing the occurrence of adverse reactions and improving the survival quality of patients， and it is worth promotion and application in clinic. 　　[Key words] Aidi injection； Non-small cell lung cancer； Chemotherapy； Cell factor； Adverse reactions 　　非小细胞肺癌是指发于支气管上皮、黏膜、腺体等部位的?盒灾琢觯?发病率逐年升高，化疗是常用的治疗方法，但是化疗的不良反应多，患者耐受力低，从而影响到化疗的顺利进行，影响治疗效果[1-2]。艾迪注射液是一种中成药，其具有较强的抗肿瘤效果，有助于提高机体的免疫力[3]，将其